This site is intended for health professionals only

Wednesday 19 June 2019
Share |

Latest News

Lynparza approved for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer

Tuesday 18th June 2019
AstraZeneca and MSD have announced that the European Commission (EC) has approved Lynparza (olaparib) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
The licensed indication is as a maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (...
Thu, 23 May 2019
Inotersen is the world’s first and only subcutaneous RNA-targeting drug designed to reduce the production of human transthyretin protein
Thu, 23 May 2019
Inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate) was superior to the standard of care (long-acting beta-agonist/inhaled corticosteroid) in terms of lung function in a Phase II study
Wed, 22 May 2019
The worse outcome in women is largely attributable to the fact that women had about half the chance of having a shockable initial rhythm compared to men
Wed, 22 May 2019
Coronary angiography is an invasive procedure that provides an X-ray outline of the arteries supplying blood to the heart but there has been controversy over when to use it
Mon, 20 May 2019
Over 870,000 people have taken part in clinical trials in 2018/2019 and this number marks a significant step towards the NHS Long Term Plan’s goal of reaching one million participants by 2023/24
Fri, 17 May 2019
Experts would be able to see, for the first time, how a particular drug works within a patient at a cellular level or the molecular processes set in motion by a genetic mutation
Thu, 9 May 2019
The recommendation comes as a result of a significant volume of evidence that the use of PICO improves patient outcomes and provide additional benefits to the healthcare system at no extra cost versus standard care